ClinicalTrials.gg
Active, not recruitingNCT07079800Updated Jul 23, 2025

A Temporal Variability Study of Remimazolam for General Anesthesia Induction and Maintenance

An observational study in Biological Rhythm and Drug Metabolism and Pharmacokinetics, sponsored by Jie Chen. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-23.

Sponsored by Jie Chen · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
188
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study was to observe and compare the differences in plasma concentration, dosage and carboxylesterase 1 activity of remimazolam when remimazolam is used for general anesthesia induction and maintenance at different times of the day, and to explore the effect of time rhythm on the pharmacokinetics and pharmacodynamics of remimazolam, so as to provide new ideas and clinical basis for optimizing medication regimens and anesthesia management.

Read the detailed description

This study is a single-blind, prospective cohort study. It is mainly divided into two parts: 1. Detection of the blood concentration and dosage differences of remimazolam: Patients who were scheduled to undergo laparoscopic cholecystectomy under general anesthesia were included. The patients were divided into the morning group (operation time 8:00-12:00) and the afternoon group (operation time 14:00-18:00) according to the operation time. The blood concentration of remimazolam after anesthesia induction was measured, and the influence of time rhythm on the pharmacokinetics of remimazolam was statistically analyzed. The dosage of remimazolam used during anesthesia maintenance was measured, and statistical analysis was conducted on whether there were dosage differences and the temporal rhythm of drug efficacy of remimazolam during the maintenance process. 2. CES1 Activity detection: Patients who were scheduled to undergo laparoscopic partial hepatectomy under general anesthesia were included. The research subjects were divided into the morning group (8:00-12:00) and the afternoon group (14:00-18:00) based on the liver tissue sampling time. The activity of carboxylate esterase 1 (CES1) in the normal tissues adjacent to liver cancer in patients at different time points was measured. Analyze the influence of time rhythm on the drug metabolism of remimazolam. The effects of time rhythm on the pharmacokinetics and pharmacodynamics of remimazolam were jointly verified from three aspects: blood drug concentration, drug dosage, and CES1 activity.

02

Conditions studied

  • Biological Rhythm
  • Drug Metabolism and Pharmacokinetics
03

In context

Lead sponsor

Jie Chen is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Experiment 1: Measurement Experiment of Remimazolam Blood Concentration and Dosage

  1. Age 18-65 years old, ASAI-II class, BMI18.5-25kg/m\^2;
  2. Inpatients undergoing laparoscopic cholecystectomy;
  3. The estimated time of operation is 1.5\~2.5 hours;
  4. Voluntary participation and signed informed consent.

Experiment 2: Remimazolam metabolic enzyme CES1 activity measurement experiment

  1. Age 18-75 years old, ASAI-III class;
  2. Inpatients undergoing laparoscopic partial hepatic resection;
  3. Voluntary participation and signed informed consent.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Experiment 1: Measurement Experiment of Remimazolam Blood Concentration and Dosage

  1. Age 18-65 years old, ASAI-II class, BMI18.5-25kg/m\^2;
  2. Inpatients undergoing laparoscopic cholecystectomy;
  3. The estimated time of operation is 1.5\~2.5 hours;
  4. Voluntary participation and signed .

Experiment 2: Remimazolam metabolic enzyme CES1 activity measurement experiment

  1. Age 18-75 years old, ASAI-III class;
  2. Inpatients undergoing laparoscopic partial hepatic resection;
  3. Voluntary participation and signed informed consent.

Exclusion criteria

Exclusion Criteria:

Experiment 1:Measurement Experiment of Remimazolam Blood Concentration and Dosage

  1. Pregnant or lactating women;
  2. Patients who are allergic to remazolam or ;
  3. Patients who are dependent on or tolerant to opioids or have long-term alcoholism;
  4. Serious cardiovascular system, respiratory system, liver and kidney diseases;
  5. History of obstructive sleep apnea;
  6. Mental disorders or neurological diseases;
  7. Patients who participated in clinical trials of other drugs within the last 3 months;
  8. The attending physician or researcher considers that there are other circumstances that are not suitable for participation in this study;
  9. Refuse to participate in the study

Experiment 2: Remimazolam metabolic enzyme CES1 activity measurement experiment

  1. Pregnant or lactating women;
  2. Patients who are allergic to remazolam or contraindicated;
  3. Patients who are dependent on or tolerant to opioids or have long-term alcoholism;
  4. Serious cardiovascular system, respiratory system;
  5. History of obstructive sleep apnea;
  6. Mental disorders or neurological diseases;
  7. Patients who participated in clinical trials of other drugs within the last 3 months;
  8. The attending physician or researcher considers that there are other circumstances that are not suitable for participation in this study;
  9. Refuse to participate in the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
188 participants (actual)
Patient registry
No

Groups and cohorts

  • Remimazolam blood concentration and dosage measurement experiment Morning group
  • Remimazolam blood concentration and dosage measurement experiment Afternoon group
  • Remimazolam metabolic enzyme CES1 activity measurement experiment morning group
  • Remimazolam metabolizing enzyme CES1 activity measurement experiment afternoon group
06

What researchers measure

Primary outcomes

  1. Remimazolam dosage

    During the maintenance of anesthesia, adjust the infusion rate of remimazolam to maintain the BIS value at 40-60, and record the dosage of remimazolam

    Time frame: During the operation

  2. Remimazolam blood concentration

    Arterial blood of 2 ml was collected immediately after the end of remimazolam infusion during the anesthesia induction period and 6 minutes after the end of infusion, respectively. After each sample collection, rinse the ductus arteriosus with 1 ml of normal saline. The blood sample was drawn into a plastic tube containing ethylenediaminetetraacetic acid and stored at 4℃. Centrifuge the blood sample within 10 minutes after collection. Transfer the supernatant plasma into a polypropylene tube within 15 minutes after separation and store it immediately at -20℃. Blood samples should be stored at -80℃ within 4 hours after collection. The blood concentration of remimazolam and the concentration of its metabolite CNS7054 were determined by ultra-performance liquid chromatography-tandem mass spectrometry within two weeks after blood collection.

    Time frame: Within two weeks after the operation

  3. CES1 activity

    When a surgeon removes a liver tumor, 50 mg of normal liver tissue adjacent to the tumor is quickly taken. The liver tissue is rinsed with normal saline, dried with filter paper, and placed in a cryotube. It is then rapidly frozen in liquid nitrogen and stored in a -80 ° C refrigerator for subsequent determination of CES1 enzyme activity by enzyme-linked immunosorbent assay.

    Time frame: Within two weeks after the operation

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Jun 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2025
First posted
Jul 23, 2025
StartActual
Jun 17, 2025
Primary completionEst.
Jun 20, 2026
CompletionEst.
Jul 20, 2026
Last update
Jul 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07079800
Lead sponsor
Jie Chen
Responsible party
Jie Chen (Clinical Professor, The Second Affiliated Hospital of Chongqing Medical University) — Sponsor-investigator
First posted
Jul 23, 2025
Start date
Jun 17, 2025
Primary completion
Jun 20, 2026 (estimated)
Completion
Jul 20, 2026 (estimated)
Last update
Jul 23, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion